The U.S. Food and Drug Administration on Tuesday approved Pfizer's (PFE.N, opens new tab RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
In June, the U.S. CDC narrowed its recommendation for the use of respiratory syncytial virus vaccines in older adults this year and held off on recommending their use for adults under age 60.
